Acquiring Company
Aurinia Pharmaceuticals
Acquired Company
Kezar Life Sciences
Description
Aurinia Pharmaceuticals has successfully acquired Kezar Life Sciences through a cash and stock merger. Under the terms, former shareholders of Kezar will receive $6.9550 in cash plus one share in the post-merger entity. This merger offers a combined value that includes both immediate cash compensation and equity participation in the new company.
Who to call at Aurinia Pharmaceuticals, and when
When Aurinia Pharmaceuticals changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Aurinia Pharmaceuticals raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Aurinia Pharmaceuticals, from your own LinkedIn network
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Aurinia Pharmaceuticals makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Frequently asked
Who acquired Kezar Life Sciences?
Kezar Life Sciences was acquired by Aurinia Pharmaceuticals. The deal was reported on August 29, 2026. Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of kidney diseases. Aurinia Pharmaceuticals is publicly traded (AUPH) and operates in Biotechnology.
When did Aurinia Pharmaceuticals acquire Kezar Life Sciences?
Aurinia Pharmaceuticals's acquisition of Kezar Life Sciences was reported on August 29, 2026. Aurinia Pharmaceuticals has successfully acquired Kezar Life Sciences through a cash and stock merger. Under the terms, former shareholders of Kezar will receive $6.9550 in cash plus one share in the post-merger entity. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Kezar Life Sciences do?
Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing novel treatments for immune-mediated and oncologic disorders. It is privately held, operating in Biotechnology, and is based in California.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.